



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 848 060 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
02.02.2000 Bulletin 2000/05

(51) Int Cl.7: C12N 15/12, C12N 15/85,
C12N 5/10, C12N 1/21,
C07K 14/72, C07K 16/28,
C12Q 1/68, A61K 31/70,
A61K 38/17, A61K 48/00,
G01N 33/50, G01N 33/68

(43) Date of publication A2:
17.06.1998 Bulletin 1998/25

(21) Application number: 97309647.2

(22) Date of filing: 01.12.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: 11.12.1996 US 32763 P

(71) Applicant: SMITHKLINE BEECHAM
CORPORATION
Philadelphia Pennsylvania 19103 (US)

(72) Inventors:
• Bergsma, Derk J.
King of Prussia, Pennsylvania 19406 (US)
• Ellis, Catherine E.
King of Prussia, Pennsylvania 19406 (US)

(74) Representative:
Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)

(54) Novel human 11CB splice variant

(57) Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others. Antagonists against such an 11cb splice variant and their use as a therapeutic to treat

infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the 11cb splice variant and for detecting altered levels of the polypeptide in a host.

EP 0 848 060 A3

Printed by Jouve, 75001 PARIS (FR)